What does therapeutic development — operating income mean?

This is the net result of the therapeutic development segment's operations, calculated by subtracting operating expenses from segment revenue. It serves as the primary measure of the segment's operational profitability and financial performance.

Fulgent Genetics, Inc. FLGT Therapeutic Development — Operating Income

Other segment segments

Laboratory Services

-$15.22M-407%

Similar metrics at other companies

DNLITherapeutics Segment — Operating Income (Loss)

-$137.36M+5.6%

ASYSThermal Processing Solutions — Operating Income

$3.16M+138%

GKOSDevelopment And Commercialization Of Ophthalmic Therapies — Net Income Loss

-$19.78M-9.0%

DNLITherapeutics Segment — Income (Loss) Attributable to Parent, before Tax

-$128.45M+3.4%

MCDInternational Developmental Licensed Markets and Corporate — Operating Income (Loss)

$67M+17.5%

FRPHDevelopment — Operating profit (loss):

$167K+96.5%

Other financials

Income statement

See full

Revenue$71.1M-3.2%

Gross profit$21.5M-24.2%

Operating income-$34.6M-74.9%

Net income-$24.8M-115%

EPS (diluted)-$0.80-116%

Balance sheet

See full

Cash & equivalents$23.4M-65.2%

Total debt$8.2M+40.5%

Total equity$1.0B-6.9%

Total assets$1.2B-4.1%

Cash flow

See full

Operating cash flow$7.1M+260%

CapEx$5.2M+10.3%

Free cash flow$1.9M+121%

Valuation

See full

Market cap$552.11M-7.1%

Enterprise value$536.92M+0.7%

P/S1.7×-0.3×

Profitability

See full

Gross margin38.7%-0.1pp

Operating margin-33.1%+17.4pp

Net margin-23%+43.3pp

FCF margin-36.9%—

Returns & leverage

See full

Return on equity-6.8%+48.2pp

Debt / equity0×0.0×

Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — operating income.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s therapeutic development — operating income?: Fulgent Genetics, Inc. (FLGT) reported therapeutic development — operating income of -$4.46M in Q1 2026.
How has Fulgent Genetics, Inc.'s therapeutic development — operating income changed year-over-year?: Fulgent Genetics, Inc.'s therapeutic development — operating income decreased by 4.8% year-over-year, from -$4.25M to -$4.46M.
What does therapeutic development — operating income mean?: This is the net result of the therapeutic development segment's operations, calculated by subtracting operating expenses from segment revenue. It serves as the primary measure of the segment's operational profitability and financial performance.